BIOIMPACT CAPITAL LLC Holdings

BIOIMPACT CAPITAL LLC is an investment fund managing more than 422.22M US dollars. The largest holdings include Cullinan Oncology, iTeos Therapeutics and Inhibrx. In Q3 2022 the fund bought assets of total value of 80.85M US dollars and sold assets of total value of 6.49M US dollars.

$422.22M

portfolio value

+1.38%

quarter

-43.06%

1 year

BIOIMPACT CAPITAL LLC portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2020	13786000	24926000
Q2 2020	142430000	6561000
Q4 2020	76849000	8737000
Q1 2021	329772000	46148000
Q2 2021	41647000	73496000
Q4 2021	38410000	30114000
Q1 2022	18301000	95103000
Q2 2022	41044000	21588000
Q3 2022	80846000	6485000

BIOIMPACT CAPITAL LLC 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology Cullinan Oncology, Inc. Portfolio share: 23.22% Portfolio value: 98.05M Avg. open price: N/A Current price: $11.61 P/L: N/A N/A Q3 2021	share	23.22%	98.05M	N/A	$11.61	N/A	N/A Q3 2021
Biotechnology iTeos Therapeutics, Inc. Portfolio share: 7.88% Portfolio value: 33.26M Avg. open price: N/A Current price: $20.04 P/L: N/A Sold -5.35% shares Q1 2022	share	7.88%	33.26M	N/A	$20.04	N/A	Sold -5.35% shares Q1 2022
Biotechnology Inhibrx, Inc. Portfolio share: 5.44% Portfolio value: 22.97M Avg. open price: $11.35 Current price: $29.18 P/L: +157.09% Bought +25.08% shares Q3 2022	share	5.44%	22.97M	$11.35	$29.18	+157.09%	Bought +25.08% shares Q3 2022
Biotechnology Verve Therapeutics, Inc. Portfolio share: 5.17% Portfolio value: 21.83M Avg. open price: N/A Current price: $21.42 P/L: N/A N/A Q3 2022	share	5.17%	21.83M	N/A	$21.42	N/A	N/A Q3 2022
Biotechnology Intellia Therapeutics, Inc. Portfolio share: 4.96% Portfolio value: 20.95M Avg. open price: $65.38 Current price: $42.01 P/L: -35.74% Bought +25.05% shares Q3 2022	share	4.96%	20.95M	$65.38	$42.01	-35.74%	Bought +25.05% shares Q3 2022
Biotechnology Repare Therapeutics Inc. Portfolio share: 4.71% Portfolio value: 19.89M Avg. open price: N/A Current price: $16.49 P/L: N/A N/A Q3 2021	share	4.71%	19.89M	N/A	$16.49	N/A	N/A Q3 2021
Biotechnology Geron Corporation Portfolio share: 4.67% Portfolio value: 19.70M Avg. open price: $1.34 Current price: $2.29 P/L: +70.97% Sold -0.15% shares Q3 2022	share	4.67%	19.70M	$1.34	$2.29	+70.97%	Sold -0.15% shares Q3 2022
Biotechnology IVERIC bio, Inc. Portfolio share: 4.46% Portfolio value: 18.83M Avg. open price: N/A Current price: $21.89 P/L: N/A N/A Q3 2022	share	4.46%	18.83M	N/A	$21.89	N/A	N/A Q3 2022
Biotechnology Merus N.V. Portfolio share: 4.36% Portfolio value: 18.39M Avg. open price: N/A Current price: $14.2 P/L: N/A Sold -0.13% shares Q3 2022	share	4.36%	18.39M	N/A	$14.2	N/A	Sold -0.13% shares Q3 2022
Biotechnology REGENXBIO Inc. Portfolio share: 3.88% Portfolio value: 16.36M Avg. open price: N/A Current price: $23.04 P/L: N/A N/A Q3 2022	share	3.88%	16.36M	N/A	$23.04	N/A	N/A Q3 2022
Biotechnology Iovance Biotherapeutics, Inc. Portfolio share: 3.86% Portfolio value: 16.28M Avg. open price: $11.04 Current price: $8.03 P/L: -27.26% Bought +41.67% shares Q3 2022	share	3.86%	16.28M	$11.04	$8.03	-27.26%	Bought +41.67% shares Q3 2022
Biotechnology Werewolf Therapeutics, Inc. Portfolio share: 2.55% Portfolio value: 10.77M Avg. open price: N/A Current price: $1.75 P/L: N/A N/A Q3 2021	share	2.55%	10.77M	N/A	$1.75	N/A	N/A Q3 2021
Biotechnology G1 Therapeutics, Inc. Portfolio share: 2.53% Portfolio value: 10.70M Avg. open price: N/A Current price: $6.17 P/L: N/A Sold -0.43% shares Q4 2021	share	2.53%	10.70M	N/A	$6.17	N/A	Sold -0.43% shares Q4 2021
Biotechnology Cytokinetics, Incorporated Portfolio share: 2.22% Portfolio value: 9.36M Avg. open price: N/A Current price: $38.12 P/L: N/A Sold -0.54% shares Q3 2022	share	2.22%	9.36M	N/A	$38.12	N/A	Sold -0.54% shares Q3 2022
Biotechnology BioCryst Pharmaceuticals, Inc. Portfolio share: 1.81% Portfolio value: 7.63M Avg. open price: N/A Current price: $11.58 P/L: N/A Sold -5.23% shares Q3 2022	share	1.81%	7.63M	N/A	$11.58	N/A	Sold -5.23% shares Q3 2022
Biotechnology Crinetics Pharmaceuticals, Inc. Portfolio share: 1.70% Portfolio value: 7.16M Avg. open price: $21.05 Current price: $18.32 P/L: -12.97% Sold -0.54% shares Q3 2022	share	1.70%	7.16M	$21.05	$18.32	-12.97%	Sold -0.54% shares Q3 2022
Biotechnology Travere Therapeutics, Inc. Portfolio share: 1.61% Portfolio value: 6.81M Avg. open price: N/A Current price: $20.01 P/L: N/A Sold -0.54% shares Q3 2022	share	1.61%	6.81M	N/A	$20.01	N/A	Sold -0.54% shares Q3 2022
Biotechnology Y-mAbs Therapeutics, Inc. Portfolio share: 1.52% Portfolio value: 6.39M Avg. open price: N/A Current price: $4.43 P/L: N/A Sold -0.62% shares Q1 2022	share	1.52%	6.39M	N/A	$4.43	N/A	Sold -0.62% shares Q1 2022
Biotechnology TCR2 Therapeutics Inc. Portfolio share: 1.44% Portfolio value: 6.06M Avg. open price: N/A Current price: $1.37 P/L: N/A N/A Q3 2021	share	1.44%	6.06M	N/A	$1.37	N/A	N/A Q3 2021
Biotechnology Harmony Biosciences Holdings, Inc. Portfolio share: 1.43% Portfolio value: 6.05M Avg. open price: N/A Current price: $60.91 P/L: N/A Sold -0.54% shares Q3 2022	share	1.43%	6.05M	N/A	$60.91	N/A	Sold -0.54% shares Q3 2022
Biotechnology Arcutis Biotherapeutics, Inc. Portfolio share: 1.16% Portfolio value: 4.91M Avg. open price: N/A Current price: $17.35 P/L: N/A Sold -0.51% shares Q3 2022	share	1.16%	4.91M	N/A	$17.35	N/A	Sold -0.51% shares Q3 2022
Biotechnology Reata Pharmaceuticals, Inc. Portfolio share: 1.07% Portfolio value: 4.5M Avg. open price: N/A Current price: $39.62 P/L: N/A Sold -0.52% shares Q3 2022	share	1.07%	4.5M	N/A	$39.62	N/A	Sold -0.52% shares Q3 2022
Biotechnology Amicus Therapeutics, Inc. Portfolio share: 0.97% Portfolio value: 4.10M Avg. open price: N/A Current price: $12.37 P/L: N/A Sold -20.71% shares Q3 2022	share	0.97%	4.10M	N/A	$12.37	N/A	Sold -20.71% shares Q3 2022
Biotechnology Provention Bio, Inc. Portfolio share: 0.79% Portfolio value: 3.33M Avg. open price: $4 Current price: $8.94 P/L: +123.50% Bought +24.97% shares Q3 2022	share	0.79%	3.33M	$4	$8.94	+123.50%	Bought +24.97% shares Q3 2022
Biotechnology Harpoon Therapeutics, Inc. Portfolio share: 0.73% Portfolio value: 3.10M Avg. open price: N/A Current price: $0.72 P/L: N/A N/A Q3 2021	share	0.73%	3.10M	N/A	$0.72	N/A	N/A Q3 2021
Biotechnology Edgewise Therapeutics, Inc. Portfolio share: 0.71% Portfolio value: 2.99M Avg. open price: N/A Current price: $8.83 P/L: N/A N/A Q3 2022	share	0.71%	2.99M	N/A	$8.83	N/A	N/A Q3 2022
Biotechnology Madrigal Pharmaceuticals, Inc. Portfolio share: 0.69% Portfolio value: 2.90M Avg. open price: N/A Current price: $72.87 P/L: N/A Sold -0.56% shares Q3 2022	share	0.69%	2.90M	N/A	$72.87	N/A	Sold -0.56% shares Q3 2022
Biotechnology Revolution Medicines, Inc. Portfolio share: 0.68% Portfolio value: 2.88M Avg. open price: N/A Current price: $24.32 P/L: N/A Sold -2.64% shares Q4 2021	share	0.68%	2.88M	N/A	$24.32	N/A	Sold -2.64% shares Q4 2021
Biotechnology Verastem, Inc. Portfolio share: 0.65% Portfolio value: 2.75M Avg. open price: $3.08 Current price: $0.42 P/L: -86.36% Sold -0.82% shares Q1 2022	share	0.65%	2.75M	$3.08	$0.42	-86.36%	Sold -0.82% shares Q1 2022
Biotechnology Phathom Pharmaceuticals, Inc. Portfolio share: 0.51% Portfolio value: 2.14M Avg. open price: N/A Current price: $11.07 P/L: N/A N/A Q1 2022	share	0.51%	2.14M	N/A	$11.07	N/A	N/A Q1 2022
Drug Manufacturers—Specialty & Generic Avadel Pharmaceuticals plc Portfolio share: 0.49% Portfolio value: 2.06M Avg. open price: $8.02 Current price: $8.75 P/L: +9.10% Bought +9.87% shares Q1 2022	share	0.49%	2.06M	$8.02	$8.75	+9.10%	Bought +9.87% shares Q1 2022
Biotechnology Mirum Pharmaceuticals, Inc. Portfolio share: 0.48% Portfolio value: 2.04M Avg. open price: N/A Current price: $18.33 P/L: N/A Sold -66.27% shares Q3 2022	share	0.48%	2.04M	N/A	$18.33	N/A	Sold -66.27% shares Q3 2022
Biotechnology Oncorus, Inc. Portfolio share: 0.48% Portfolio value: 2.02M Avg. open price: N/A Current price: $0.44 P/L: N/A N/A Q3 2021	share	0.48%	2.02M	N/A	$0.44	N/A	N/A Q3 2021
Biotechnology Inozyme Pharma, Inc. Portfolio share: 0.42% Portfolio value: 1.77M Avg. open price: $4.09 Current price: $1.36 P/L: -66.75% Sold -0.58% shares Q3 2022	share	0.42%	1.77M	$4.09	$1.36	-66.75%	Sold -0.58% shares Q3 2022
Biotechnology ADC Therapeutics SA Portfolio share: 0.38% Portfolio value: 1.61M Avg. open price: N/A Current price: $3.52 P/L: N/A Sold -0.89% shares Q1 2022	share	0.38%	1.61M	N/A	$3.52	N/A	Sold -0.89% shares Q1 2022
Biotechnology ESSA Pharma Inc. Portfolio share: 0.17% Portfolio value: 738K Avg. open price: N/A Current price: $3.47 P/L: N/A Sold -38.61% shares Q3 2022	share	0.17%	738K	N/A	$3.47	N/A	Sold -38.61% shares Q3 2022
Biotechnology AVROBIO, Inc. Portfolio share: 0.10% Portfolio value: 416K Avg. open price: N/A Current price: $0.89 P/L: N/A Sold -24.82% shares Q4 2021	share	0.10%	416K	N/A	$0.89	N/A	Sold -24.82% shares Q4 2021
Biotechnology Black Diamond Therapeutics, Inc. Portfolio share: 0.10% Portfolio value: 405K Avg. open price: N/A Current price: $1.86 P/L: N/A Sold -3.47% shares Q4 2021	share	0.10%	405K	N/A	$1.86	N/A	Sold -3.47% shares Q4 2021
Biotechnology Epizyme, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $16.06 Current price: $1.46 P/L: -90.91% Sold -100.00% shares Q3 2022	share	0.00%	0	$16.06	$1.46	-90.91%	Sold -100.00% shares Q3 2022
Diagnostics & Research NeoGenomics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $11.8 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$11.8	N/A	Sold -100.00% shares Q3 2022
Biotechnology Karuna Therapeutics, Inc. Portfolio share: 0.00% Portfolio value: 0 Avg. open price: N/A Current price: $226.95 P/L: N/A Sold -100.00% shares Q3 2022	share	0.00%	0	N/A	$226.95	N/A	Sold -100.00% shares Q3 2022

Showing TOP 41 BIOIMPACT CAPITAL's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of BIOIMPACT CAPITAL LLC?

The biggest position of the BIOIMPACT CAPITAL LLC is Cullinan Oncology, Inc. (CGEM) with 23.22% portfolio share worth of 98.05M US dollars.

Top 5 BIOIMPACT CAPITAL's holdings represent 46.68% of the portfolio:

Cullinan Oncology, Inc. (CGEM) – 23.22%
iTeos Therapeutics, Inc. (ITOS) – 7.88%
Inhibrx, Inc. (INBX) – 5.44%
Verve Therapeutics, Inc. (VERV) – 5.17%
Intellia Therapeutics, Inc. (NTLA) – 4.96%

Who is the portfolio manager of BIOIMPACT CAPITAL LLC?

The portfolio manager of the BIOIMPACT CAPITAL LLC is .

What is the total asset value of the BIOIMPACT CAPITAL LLC portfolio?

BIOIMPACT CAPITAL LLC total asset value (portfolio value) is 422.22M US dollars.

Who is ?

is the portfolio manager of the BIOIMPACT CAPITAL LLC.

What is (BIOIMPACT CAPITAL LLC) fund performance?

BIOIMPACT CAPITAL's quarterly performance is +1.38%, annualy -43.06%.

What is the BIOIMPACT CAPITAL LLC CIK?

BIOIMPACT CAPITAL's Central Index Key is 0001687078 .